dose escalation — my 2-week log, condensed into one table
Posting this as a discussion rather than a claim: dose escalation — my 2-week log, condensed into one table. Phase 2 estimates effect and finds a dose range. Phase 3 estimates it precisely in a bigger population and catches what phase 2 was too small to see. Treating them as the same tier of evidence is the recurring…
This. The phase 2 result was genuinely large and it was also 48 weeks in a few hundred people.
Sent a vial to Medutest out of curiosity. Result was 97.2% against a claimed 97.0%, which is the first independent number I had seen for this compound anywhere.
heart rate is the thing people report watching
Push back: quoting the phase 2 headline as an expected outcome is not a fair reading of a small trial with wide intervals.
It is a triple agonist at the GLP-1, GIP and glucagon receptors. The glucagon arm is the genuinely novel component and it is the one with the least human outcome data behind it.
Disagree. "More receptors means more effect" is not how any of this works and the trial data does not support the linear story.
the TRIUMPH programme is still running, so anything definitive is premature
Glucagon receptor agonism is associated with increased energy expenditure and with hepatic effects. That is a mechanistic story with strong preclinical support and limited phase 2 human data.
comparing reta phase 2 to sema phase 3 is comparing different things